Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, 5001 El Paso Dr, El Paso, TX 79905, USA.
College of Physicians and Surgeons, Columbia University Medical Center, 630 W 168th Street, New York, NY 10032, USA; Society Hill Dermatology, 932 Pine Street, Philadelphia, PA 19107, USA.
Dermatol Clin. 2014 Apr;32(2):123-35. doi: 10.1016/j.det.2013.12.008.
Facial hyperpigmentation is common and challenging to treat in darker-skinned populations. A Medline literature search of articles published up to October 2013 reporting the objective assessment of and/or treatment for melasma, postinflammatory hyperpigmentation, dermatosis papulosa nigra, lichen planus pigmentosus, and erythema dyschromicum perstans was reviewed. Objective assessment was only reported for melasma and postinflammatory hyperpigmentation. Furthermore, randomized controlled trial evidence was only reported for melasma. Although progress has been made, there is a need to develop more objective outcome measures and effective treatments for hyperpigmentation.
面部色素沉着在肤色较深的人群中很常见，也很难治疗。对截至 2013 年 10 月发表的评估黄褐斑、炎症后色素沉着、黑棘皮病、扁平苔藓色素沉着和持久性色素异常性红斑的客观评估和/或治疗的 Medline 文献进行了回顾。仅对黄褐斑和炎症后色素沉着进行了客观评估。此外，仅对黄褐斑报道了随机对照试验证据。尽管已经取得了一些进展，但仍需要开发更客观的疗效评估方法和更有效的治疗方法来治疗色素沉着。
